EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression

Acta Neuropathol Commun. 2020 Nov 5;8(1):183. doi: 10.1186/s40478-020-01056-8.

C Antin¹, A Tauziède-Espariat², M-A Debily^{3

4}, D Castel^{3

5}, J Grill^{3

5}, M Pagès¹, O Ayrault^{6

7}, F Chrétien¹, A Gareton¹, F Andreiuolo¹, E Lechapt¹, P Varlet¹

¹ Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France.
² Department of Neuropathology, GHU Paris-Neurosciences, Sainte-Anne Hospital, 1, rue Cabanis, 75014, Paris, France. a.tauziede-espariat@ghu-paris.fr.
³ UMR8203, Vectorologie et thérapeutiques anticancéreuses, CNRS, Gustave Roussy, Univ. Paris-Sud, Univ. Paris-Saclay, 94805, Villejuif Cedex, France.
⁴ Univ. Evry, Université Paris-Saclay, 91057, Evry Cedex, France.
⁵ Department of Pediatric Oncology, Gustave Roussy Institute, Univ. Paris-Sud, Universite Paris-Saclay, 94805, Villejuif, France.
⁶ CNRS UMR, INSERM, Institut Curie, PSL Research University, 91898, Orsay, France.
⁷ CNRS UMR 3347, INSERM U1021, Université Paris Sud, Université Paris-Saclay, 91898, Orsay, France.

No abstract available

Publication types